



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.
 Corporate Office : Energy IT Park, Unit A2, 3rd Floor, Unit A, 8th Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai – 400 025.
 Phone: 022-2439 5200 / 2439 5500 Fax : 022 – 2431 5331/ 24131 5334
 CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2019

Sl.No.	PART I - Particulars	Quarter ended			Half Year ended		Year ended
		30-09-2019	30-06-2019	30-09-2018	30-09-2019	30-09-2018	31-03-2019
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	42,812.42	41,080.05	40,420.42	83,892.47	77,011.10	1,50,118.70
2	Other Income	1,810.70	1,233.75	817.52	3,044.45	935.73	4,022.50
3	Total Income (1+2)	44,623.12	42,313.80	41,237.94	86,936.92	77,946.83	1,54,141.20
4	Expenses						
	a. Cost of materials consumed	10,619.99	12,617.74	11,451.18	23,237.73	22,551.26	45,375.37
	b. Purchases of stock-in-trade	4,497.95	1,365.41	2,907.92	5,863.36	5,377.31	10,426.13
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	176.96	1,006.43	110.36	1,183.39	(299.23)	(2,165.74)
	d. Employee benefit expenses	6,969.05	7,064.11	6,626.02	14,033.16	12,563.72	25,797.86
	e. Finance Costs	87.43	80.37	71.57	167.80	198.80	411.51
	f. Depreciation and amortization expense	1,622.32	1,562.91	1,446.62	3,185.23	2,893.14	5,482.49
	g. Other Expenses	10,471.86	9,800.88	11,119.98	20,272.74	21,209.42	41,886.05
	Total Expenses (4)	34,445.56	33,497.85	33,733.65	67,943.41	64,494.42	1,27,213.67
5	Profit before Tax (3-4)	10,177.56	8,815.95	7,504.29	18,993.51	13,452.41	26,927.53
6	Tax expenses	581.63	2,901.31	2,360.28	3,482.94	4,101.35	8,721.61
7	Net Profit after Tax for the period (5-6)	9,595.93	5,914.64	5,144.01	15,510.57	9,351.06	18,205.92
8	Other Comprehensive Income (net of Tax)	(252.80)	(5.20)	(61.81)	(258.00)	(123.61)	29.25
9	Total Comprehensive Income after Tax (7+8)	9,343.13	5,909.44	5,082.20	15,252.57	9,227.45	18,235.17
10	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	11.96	7.37	6.16	19.33	11.19	22.15
	(2) Diluted	11.96	7.37	6.16	19.33	11.19	22.15

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on November 12, 2019.
- The auditors have carried out limited review of the financial results for the quarter and six months ended September 30, 2019 and their report does not contain any qualification.
- Indian Accounting Standard (Ind AS) - 116 " Leases" became effective from April 1, 2019 and the Company has adopted the same using modified retrospective transition method where at the date of initial application, the lease liability is measured at the present value of remaining lease payments and right of use asset has been recognised at an amount equal to the lease liability. In the statement of profit and loss for the six months ended September 30, 2019, Compensation Rent expenses has changed to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. The effect of adoption of Ind AS 116 on the results for the quarter and six months ended September 30, 2019 is not material. To this extent, performance for the quarter and six months ended September 30, 2019 is not comparable with previous period results.
- The Company has exercised the option of lower tax rate of 25.17% (inclusive of surcharge and cess) permitted under Section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. The full impact of this change has been recognized in tax expense for the quarter and six months ended September 30, 2019. This has resulted in reversal of current tax expense of Rs. 6.00 crores accrued in quarter ended June 30, 2019 and reversal of tax expenses of Rs. 13.66 crores on account of re-measurement of deferred tax liability as at March 31, 2019.
- The Board of Directors has approved the buy-back of up to 2,954,545 fully paid up equity shares of face value of Rs. 2/- each by the Company (representing 3.68% of the total paid up Equity Share capital of the Company) at a price of Rs. 440 per Equity Share for a total consideration not exceeding Rs. 130 crores (excluding Transaction costs).
- The Company has one reportable segment viz. Pharmaceuticals.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

8 STATEMENT OF STANDALONE UNAUDITED ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER 2019.

(Rs. In lakhs)

	Particulars	As at	Sept	As at
		30,2019	As at	March 31,2019
		Unaudited		Audited
	ASSETS			
(I)	Non-current assets			
	(a) Property, Plant and Equipment	56,039.24		54,254.09
	(b) Capital work-in-progress	1,949.50		1,508.99
	(c) Goodwill	-		-
	(d) Other Intangible assets	940.89		957.01
	(e) Financial Assets			
	(i) Investments	20,031.18		22,884.24
	(ii) Loans	368.48		358.86
	(iii) Others	12.56		15.82
	(f) Other non-current assets	798.75		577.87
	TOTAL non current assets	80,140.60		80,556.88
(II)	Current assets			
	(a) Inventories	20,273.02		20,810.42
	(b) Financial Assets			
	(i) Investments	52,355.63		36,064.99
	(ii) Trade receivables	32,409.92		30,092.38
	(iii) Cash and cash equivalents	1,001.99		1,936.77
	(iv) Bank balances other than (iii) above	150.67		140.03
	(v) Loans	61.17		70.95
	(vi) Others	1,417.87		1,476.34
	(c) Current Tax Assets (Net)	877.45		666.22
	(d) Other current assets	5,807.23		7,396.56
	TOTAL current assets	1,14,354.95		98,654.66
	Total Assets	1,94,495.55		1,79,211.54
	EQUITY AND LIABILITIES			
	Equity			
	(a) Equity Share capital	1,604.73		1,604.73
	(b) Other Equity	1,57,267.59		1,46,851.50
	Total Equity	1,58,872.32		1,48,456.23
	LIABILITIES			
(I)	Non-current liabilities			
	(a) Provisions	573.49		572.89
	(b) Deferred tax liabilities (Net)	6,210.52		7,115.12
	(c) Other non-current liabilities	461.91		220.29
	TOTAL non current Liabilities	7,245.92		7,908.30
(II)	Current liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	4,711.39		2,579.77
	(ii) Trade payables			
	A) Dues to Micro and Small Enterprises	476.19		787.01
	B) Due to Other than Micro and Small Enterprises	8,587.43		6,884.33
	(iii) Other financial liabilities	11,141.12		10,424.65
	(b) Other current liabilities	1,873.59		1,646.80
	(c) Provisions	291.42		134.09
	(d) Current Tax Liabilities (Net)	1,296.17		390.36
	TOTAL Current Liabilities	28,377.31		22,847.01
	Total Equity and Liabilities	1,94,495.55		1,79,211.54

9 STANDALONE CASH FLOW STATEMENT

Sr. No.	Particulars	Unaudited Six Months ended Sept 30, 2019	Unaudited Six Months ended Sept 30, 2018
A	Cash Flow from Operating Activities		
	Net Profit before Tax	18,993.51	13,452.41
	Adjustment For		
	Depreciation	3,185.23	2,893.14
	Foreign Exchange Fluctuation (Net)	(301.73)	(723.15)
	Interest expense	65.42	182.19
	Interest Expense Lease liability	42.32	-
	(Profit)/ Loss on Sale/Discard of Assets (Net)	(94.76)	1.59
	Profit on sale of Investment designated as FVTPL	(67.50)	(630.63)
	Net (Gain)/Loss arising from Financial instruments designated as FVTPL	(2,328.99)	(258.67)
	Interest income	(79.48)	(16.39)
	Dividend income	(53.75)	(16.58)
	Government Grant	(41.06)	(31.47)
	Re-measurement of the defined benefit plan	(344.77)	(190.00)
	Excess provision written back	(213.47)	-
	Operating Profit Before Working Capital Changes	18,760.97	14,662.44
	Trade Receivables	(1,924.29)	(2,631.10)
	Other Receivables	1,663.50	754.63
	Inventories	537.40	(1,417.32)
	Trade Payables	1,300.77	(649.87)
	Other Payables & Provisions	(506.95)	823.53
	Cash Generated From Operations	19,831.40	11,542.31
	Direct Taxes Paid (net)	(3,606.18)	(2,602.24)
	Net Cash from Operating Activities	16,225.22	8,940.07
B	Cash Flow from Investing Activities		
	Purchase of Fixed Assets	(3,580.87)	(2,434.48)
	Sale of Fixed Assets	95.15	110.28
	Purchase of Investment	(23,503.29)	(21,370.97)
	Sale of Investment	12,462.21	15,179.59
	(Increase)/Decrease in other bank balances	(10.64)	(11.97)
	Interest Received	81.20	17.64
	Dividend Received	53.75	16.58
	Net Cash used in Investing Activities	(14,402.49)	(8,493.33)
C	Cash Flow from Financing Activities		
	Interest Paid	(65.42)	(182.19)
	Dividend Paid (Including Dividend Distribution Tax)	(4,823.72)	(1,989.04)
	Net Cash Used in Financing Activities	(4,889.14)	(2,171.23)
	Net Increase in Cash and Cash Equivalents A+B+C	(3,066.41)	(1,724.49)
	Cash and Cash Equivalents as at 1st April	1,611.26	708.92
	Cash and Cash Equivalents as at 30th September	(1,455.15)	(1,015.57)

The above cash flow statement is prepared using the "indirect method" set out in Ind AS 7-"Statement of Cash Flows".

For J.B. Chemicals & Pharmaceuticals Ltd.



J.B.Mody
Chairman & Managing Director

Place : Mumbai
Date : 12/11/2019



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.
 Corporate Office : Energy IT Park, Unit A2, 3rd Floor, Unit A, 8th Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai – 400 025.
 Phone: 022-2439 5200 / 2439 5500 Fax : 022 – 2431 5331/ 24131 5334
 CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2019

Sl.No.	PART I - Particulars	Quarter ended			Half Year ended		(Rs. in lakhs)
		30-09-2019	30-06-2019	30-09-2018	30-09-2019	30-09-2018	31-03-2019
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	45,641.70	44,611.03	43,534.26	90,252.73	84,225.87	1,64,320.04
2	Other Income	1,850.85	1,260.80	855.26	3,111.65	996.87	4,143.99
3	Total Income (1+2)	47,492.55	45,871.83	44,389.52	93,364.38	85,222.74	1,68,464.03
4	Expenses						
	a. Cost of materials consumed	10,582.95	12,617.74	11,451.18	23,200.69	22,551.26	45,375.37
	b. Purchases of stock-in-trade	6,190.59	3,096.97	4,384.36	9,287.56	8,890.23	16,209.91
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(102.98)	960.15	115.75	857.17	(831.50)	(1,939.38)
	d. Employee benefit expenses	7,702.17	7,805.41	7,375.10	15,507.58	14,121.50	28,817.59
	e. Finance Costs	87.39	80.37	76.43	167.76	204.32	419.81
	f. Depreciation and amortization expense	1,638.65	1,579.79	1,469.20	3,218.44	2,938.16	5,564.20
	g. Other Expenses	11,242.85	10,532.85	12,057.56	21,775.70	23,261.88	45,317.27
	Total Expenses (4)	37,341.62	36,673.28	36,929.58	74,014.90	71,135.85	1,39,764.77
5	Profit before Tax (3-4)	10,150.93	9,198.55	7,459.94	19,349.48	14,086.89	28,699.26
6	Tax expenses	774.62	2,987.42	2,312.81	3,762.04	4,364.07	9,302.29
7	Net Profit after Tax for the period (5-6)	9,376.31	6,211.13	5,147.13	15,587.44	9,722.82	19,396.97
8	Other Comprehensive Income (net of Tax)	(572.27)	191.64	206.75	(380.63)	(64.36)	(419.64)
9	Total Comprehensive Income after Tax (7+8)	8,804.04	6,402.77	5,353.88	15,206.81	9,658.46	18,977.33
10	Net Profit after Tax for the period attributable to:						
	- owners of the company	9,362.41	6,200.65	5,132.87	15,563.06	9,695.43	19,346.63
	- non controlling interest	13.90	10.48	14.26	24.38	27.39	50.34
11	Other comprehensive income for the period attributable to:						
	- owners of the company	(548.54)	182.55	215.40	(365.99)	(23.79)	(372.44)
	- non controlling interest	(23.73)	9.09	(8.65)	(14.64)	(40.57)	(47.20)
12	Total Comprehensive Income after Tax attributable to:						
	- owners of the company	8,813.87	6,383.20	5,348.27	15,197.07	9,671.64	18,974.19
	- non controlling interest	(9.83)	19.57	5.61	9.74	(13.18)	3.14
13	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	11.67	7.73	6.14	19.40	11.60	23.54
	(2) Diluted	11.67	7.73	6.14	19.40	11.60	23.54

Notes

- The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on November 12, 2019.
- The auditors have carried out limited review of the consolidated financial results for the quarter and six months ended on September 30, 2019 and their report does not contain any qualification.
- The consolidated financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements.
- Indian Accounting Standard (Ind AS) - 116 "Leases" became effective from April 1, 2019 and the Group has adopted the same using modified retrospective transition method where at the date of initial application, the lease liability is measured at the present value of remaining lease payments and right of use asset has been recognised at an amount equal to the lease liability. In the statement of profit and loss for the six months ended September 30, 2019, Compensation Rent expenses has changed to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. The effect of adoption of Ind AS 116 on the results for the quarter and six months ended September 30, 2019 is not material. To this extent, performance for the quarter and six months ended September 30, 2019 is not comparable with previous period results.
- The Holding Company has exercised the option of lower tax rate of 25.17% (inclusive of surcharge and cess) permitted under Section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. The full impact of this change has been recognized in tax expense for the quarter and six months ended September 30, 2019. This has resulted in reversal of current tax expense of Rs. 6.00 crores accrued in quarter ended June 30, 2019 and reversal of tax expenses of Rs. 13.66 crores on account of re-measurement of deferred tax liability as at March 31, 2019.
- The Board of Directors of Holding Company has approved the buy-back of up to 2,954,545 fully paid up equity shares of face value of Rs. 2/- each by the Company (representing 3.68% of the total paid up Equity Share capital of the Holding Company) at a price of Rs. 440 per Equity Share for a total consideration not exceeding Rs. 130 crores (excluding Transaction costs).
- The Group has one reportable segment viz. Pharmaceuticals.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

(Rs. in lakhs)

Particulars	As at	As at
	Sept 30,2019	March 31,2019
	Unaudited	Audited
ASSETS		
(I) Non-current assets		
(a) Property, Plant and Equipment	56,252.36	54,441.67
(b) Capital work-in-progress	1,949.50	1,508.99
(c) Goodwill	5,314.00	5,314.00
(d) Other Intangible assets	2,285.31	2,337.75
(e) Financial Assets		
(i) Investments	6,734.50	9,587.56
(ii) Loans	368.48	358.86
(iii) Others	12.56	15.82
(f) Other non-current assets	798.75	577.87
TOTAL non current assets	73,715.46	74,142.52
(II) Current assets		
(a) Inventories	24,201.63	24,375.76
(b) Financial Assets	-	-
(i) Investments	52,355.63	36,064.99
(ii) Trade receivables	33,318.13	30,929.53
(iii) Cash and cash equivalents	3,389.06	3,539.68
(iv) Bank balances other than (iii) above	150.67	140.03
(v) Loans	71.73	140.23
(vi) Others	1,462.45	1,505.22
(c) Current Tax Assets (Net)	900.58	715.06
(d) Other current assets	6,016.91	7,547.03
TOTAL current assets	1,21,866.79	1,04,957.53
Total Assets	1,95,582.25	1,79,100.05
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	1,604.73	1,604.73
(b) Other Equity	1,56,768.10	1,46,407.51
(c) non controlling interest	290.07	280.33
Total Equity	1,58,662.90	1,48,292.57
LIABILITIES		
(I) Non-current liabilities		
(a) Provisions	573.49	572.89
(b) Deferred tax liabilities (Net)	4,837.52	5,690.73
(c) Other non-current liabilities	461.91	220.29
TOTAL non current Liabilities	5,872.92	6,483.91
(II) Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	4,711.39	2,579.77
(ii) Trade payables	-	-
A) Dues to Micro and Small Enterprises	476.19	787.01
B) Due to Other than Micro and Small Enterprises	10,266.54	7,489.05
(iii) Other financial liabilities	11,849.37	11,000.19
(b) Other current liabilities	1,875.67	1,676.17
(c) Provisions	424.97	397.72
(d) Current Tax Liabilities (Net)	1,442.30	393.66
TOTAL Current Liabilities	31,046.43	24,323.57
Total Equity and Liabilities	1,95,582.25	1,79,100.05

CONSOLIDATED CASH FLOW STATEMENT

Sr. No.	Particulars	Unaudited Six Months ended Sept 30, 2019	Unaudited Six Months ended Sept 30, 2018
A	Cash Flow from Operating Activities		
	Net Profit before Tax	19,349.47	14086.89
	Adjustment For		
	Depreciation	3,218.44	2,938.16
	Foreign Exchange Fluctuation (Net)	(400.19)	(681.83)
	Interest expense	65.42	187.71
	Interest Expense Lease liability	42.32	-
	(Profit)/ Loss on Sale/Discard of Assets (Net)	(94.76)	(5.76)
	Profit on sale of Investment designated as FVTPL	(67.50)	(630.63)
	Net (Gain)/Loss arising from Financial instruments designated	(2,328.99)	(258.67)
	Interest income	(140.91)	(56.85)
	Dividend income	(53.75)	(16.58)
	Government Grant	(41.06)	(31.47)
	Re-measurement of the defined benefit plan	(344.77)	(190.00)
	Excess provision written back	(213.47)	(1.76)
	Provision for Doubtful debts/Bad Debts	-	1.94
	Operating Profit Before Working Capital Changes	18,990.25	15,341.15
	Trade Receivables	(1,995.35)	(2,540.83)
	Other Receivables	1,647.16	1,061.85
	Inventories	174.13	(1,715.49)
	Trade Payables	2,375.15	(1,104.42)
	Other Payables & Provisions	(544.80)	529.75
	Cash Generated From Operations	20,646.54	11,572.01
	Direct Taxes Paid (net)	(3,655.26)	(2,762.65)
	Net Cash from Operating Activities	16,991.28	8,809.36
B	Cash Flow from Investing Activities		
	Purchase of Fixed Assets	(3,637.51)	(2,460.32)
	Sale of Fixed Assets	95.15	118.15
	Purchase of Investment	(23,503.29)	(21,370.97)
	Sale of Investment	12,462.21	15,179.59
	(Increase)/Decrease in other bank balances	(10.64)	(11.97)
	Interest Received	142.78	58.10
	Dividend Received	53.75	16.58
	Net Cash used in Investing Activities	(14,397.55)	(8,470.84)
C	Cash Flow from Financing Activities		
	Interest Paid	(65.42)	(187.71)
	Dividend Paid (Including Dividend Distribution Tax)	(4,810.55)	(1,989.04)
	Net Cash Used in Financing Activities	(4,875.97)	(2,176.75)
	Net Increase in Cash and Cash Equivalents A+B+C	(2,282.24)	(1,838.23)
	Cash and Cash Equivalents as at 1st April	3,214.16	2,124.25
	Cash and Cash Equivalents as at 30th September	931.92	286.02

Note The above cash flow statement is prepared using the "indirect method" set out in Ind AS 7-"Statement of Cash Flows".

For J.B. Chemicals & Pharmaceuticals Ltd.



J.B.Mody
Chairman & Managing Director

Place : Mumbai
Date : 12/11/2019